Get our lovely INSIGHT 2019 conference news


Email address
First Name
Last Name
Interested in InSight 2019
Cart
<We_can_help/>

What are you looking for?

<Good_things_happen/> Welcome to Conference

How do psychotropic drugs work?

Psychotropic drugs (here: prescription drugs) represent a mainstay in the treatment of many psychiatric disorders since the 1950s, and they have profoundly changed the practice of psychiatry worldwide. While their molecular mechanisms of action are understood in detail, it is still largely unclear, however, how the binding to a certain molecular target in the brain translates into changes in mood, emotions or behavior. The main paradigm dominating psychiatry and psychopharmacology for decades is that specific molecular defects underlie psychiatric disorders, and that these defects have to and can be treated with continuous drug treatment – analogous to e.g. type 1 diabetes (“metabolic brain disorder”). This traditional view is too narrow and has to be challenged, not only because it might have led the development of new psychotropic drugs into a wrong direction. A large proportion of patients treated with the currently available drugs does not adequately respond to treatment, and an even larger proportion does not reach remission, i.e. a state of complete and enduring wellbeing. Many patients with psychiatric disorders are being treated long-term despite insufficient control of their symptoms, persisting suffering, and debilitating side-effects especially with continuous treatment. There are even indications that drug treatment actually facilitates treatment resistance in some patients. – Psychedelic drugs also have a defined molecular target, the 5-HT2A serotonin receptor, and at least for psilocybin it has been shown that the binding of its active metabolite to this target directly correlates with the intensity of the psychedelic state. But here again, it is completely mysterious how agonism at a neurotransmitter receptor leads to profound changes in perception of oneself, time and space. It is equally unclear, how psychedelics exert their therapeutic effects in psychiatric disorders, which seem to be surprisingly long-lasting at least in some patients. – Psychedelics challenge our current thinking of the neurobiology of psychiatric disorders, the prevailing biological treatment approaches in psychiatry and the relationship between brain function and psyche in general. This presentation will summarize the current thinking in academic psychiatry and will try to provide some future perspectives for research and clinical practice.

Speaker

Date

September 6th 2019

Time

9:30-10:00

Location

Langenbeck-Virchow-Saal
tickets
Gerhard Gründer
Prof. Dr.

Gerhard Gründer

Department of Molecular Neuroimaging, Central Institute of Mental Health, Mannheim more about the speaker
Lea Julia Mertens
M.Sc.

Lea Julia Mertens

Department of Molecular Neuroimaging, Central Institute of Mental Health, Mannheim more about the speaker

Related Events

Research with Psychedelics: Translating Lab Findings into Therapeutic Applications

Decades ago MDMA and LSD entered the therapeutic setting and already then showed their therapeutic potential in the treatment of psychiatric disorders ...

more details

Therapeutic Effects of Psilocybin

For over 15 years the Johns Hopkins Psychedelic Group has been the preeminent and most productive research team in the United States conducting human research with psychedelics...

more details

The Neurobiology and Neuropharmacology of Psychedelic-Induced Altered States of Consciousness

Psychedelics exert unique effects on consciousness. Studying these altered states and their underlying neuropharmacology and neurobiology gives us important insights into the nature of consciousness...

more details

Current Research on LSD in Healthy Subjects and Patients

Lysergic acid diethylamide (LSD) is used in Switzerland in the treatment of patients both in the context of compassionate use and in clinical studies including patients with anxiety associated with life-threatening diseases...

more details

Conference tickets

With your ticket you will have access to the whole conference - with keynotes, panels, round tables, posters and daylight social events. We will ask for a small extra fee for the Friday evening social program. The pre-conference workshops have to be booked separately and each workshop needs an individual ticket. By clicking on "Book now" below you also have the option to buy your workshop tickets.

*Reduced fees apply to students, cooperation partners as well as unemployed and retired individuals. Proof of status will be required.

Early bird

until 14 April 2019

  • Standard €170
  • Reduced €80*
  • MIND members Standard €100
  • MIND members Reduced €50

Regular

after 14 April 2019

  • Standard €250
  • Reduced €150*
  • MIND members Standard €180
  • MIND members Reduced €90

Philanthropist

 

  • Donate €600 or more
  • Invite a friend/colleague to be your VIP guest at the event

Get our lovely INSIGHT 2019 conference news


Email address
First Name
Last Name